乳腺癌原发灶与局部复发灶HR、Her—2表达差异及临床意义(3)
 |
| 第1页 |
参见附件。
[9] Guarneri V，Giovannelli S，Ficarra G，et al.Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases：impact on patient management [J].Oncologist，2008，13(8)：838-844.
[10] Idirisinghe PK， Thike AA， Cheok PY， et al.Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance[J].Am J Clin Pathol，2010，133：416-429.
[11] 管小青，吴骥，顾书成，等.ER、PR和SSTR在乳腺癌术后局部复发癌组织中的表达[J].肿瘤基础与临床，2010(23)：286-288.
[12] Cui X， Schiff R， Arpino G， et al.Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy[J].J Clin Oncol，2005，23：7721-7735.
[13] Lower EE，Glass E.HER-2/neu expression in primary and metastatic breast cancer [J].Breast Cancer Res Treat，2009， 113(2)：301-6.
[14] Santinelli A， Pisa E， Stramazzotti D， et al.HER-2 status discrepancy between primary breast cancer and metastatic sites： impact on target therapy[J]. Int J Cancer，2008，122：999-1004.
[15] Edgerton SM， Moore D， Merkel D， et al. erbB-2(HER-2)and breast cancer progression[J].Appl Immunohistochem Mol Morphol，2003，11：214-221.
[16] Lajos Pusztai， Giuseppe Viale， Catherine M， et al. Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis[J]. The Oncologist， 2010，15：1164-1168.
[17] Rhodes A， Jasani B， Balaton AJ， et al.Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in europe.Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays[J]. Am J Clin Pathol，2001，115：44-58.
(收稿日期：2013-12-26)
您现在查看是摘要介绍页，详见PDF附件。